Skip to main content

Table 2 Univariate and multivariate analyses of factors for the OS

From: Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy

   Median OS Univariate analysis Multivariate analysis
n (mean ± SD) HR 95%CI p-value HR 95%CI p-value
Age
<65 years 32 2122 (2221.6 ± 1725.5) 1 0.50-4.73 0.453    
≥65 years 42 718 (1071.4 ± 1003.6) 1.54      
Gender
Female 16 767 (1891.9 ± 1536.9) 1 0.50-12.02 0.272    
Male 58 980 (1479.6 ± 13743.5) 2.44      
ECOG-PS
0 68 1286 (1673.7 ± 1413.1) 1 0.7021.22 0.121    
≥1 6 302 (379.3 ± 319.4) 3.86      
NLR
<2.38 51 1250.5 (1576.6 ± 1375.0) 1 1.54-15.23 0.007 1 1.16-18.34 0.030
≥2.38 23 797.5 (1551.3 ± 1487.5) 4.84    4.62   
CPR
<0.08 23 1427 (1461.3 ± 1091.4) 1 1.24-81.27 0.030 1 1.06-110.29 0.045
≥0.08 51 772 (1617.2 ± 1533.2) 10.06    10.8   
LDH
<158 20 1286 (1464.7 ± 1205.3) 1 0.36-4.47 0.712    
≥158 54 808 (1607.3 ± 1565.7) 1.27      
Neoadjuvant Chemotherapy
No 64 1244 (1535.9 ± 1339.8) 1 0.15-4.10 0.772    
Yes 10 331 (1779.3 ± 2228.4) 0.78      
Clinical T stage
≤2 38 980 (1828.6 ± 1722.9) 1 0.39-3.47 0.781    
≥3 36 818 (1294.5 ± 1114.1) 1.67      
Clinical Lymph Node Metastasis
No 70 818 (1566.6 ± 1492.3) 1 0.11-11.57 0.921    
Yes 4 1671 (1607.3 ± 615.3) 1.13      
Sugical Margin
Negative 68 11271.5 (1616.1 ± 1431.6) 1 0.85-7.74 0.095    
Positive 6 707 (1287.8 ± 2064.0) 2.56      
Adjuvant chemotherapy
No 49 722 (1189.7 ± 1200.8) 1 0.48-4.52 0.493    
Yes 25 2154 (2311.7 ± 1624.5) 1.48      
Pathological T stage
≤2 53 1112 (1586.9 ± 1466.4) 1 0.32-3.52 0.914    
≥3 21 982 (1437.4 ± 1603.1) 1.07      
Pathological Lymph Node Metastasis
No 64 1244 (1609.8 ± 1466.4) 1 1.17-19.17 0.030 1 1.85-82.47 0.009
Yes 10 718 (1305.9 ± 1523.6) 4.73    12.35   
  1. OS: overall survival, ECOG-PS: Eastern Cooperative Oncology Group performance status, NLR: neutrophil-to-lymphocyte ration
  2. CPR: C-reactive protein, LHD: lactate dehydrogenase